Cost Analysis of FDG PET for Managing Patients with Ovarian Cancer.
about
Does Medicare have an implicit cost-effectiveness threshold?Role of New Functional MRI Techniques in the Diagnosis, Staging, and Followup of Gynecological Cancer: Comparison with PET-CT.Positron emission tomography in ovarian cancer: 18F-deoxy-glucose and 16alpha-18F-fluoro-17beta-estradiol PETPET and PET-CT imaging of gynecological malignancies: present role and future promise.Present and future of FDG-PET/CT in ovarian cancer.Nuclear medicine for imaging of epithelial ovarian cancer.
P2860
Cost Analysis of FDG PET for Managing Patients with Ovarian Cancer.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Cost Analysis of FDG PET for Managing Patients with Ovarian Cancer.
@en
Cost Analysis of FDG PET for Managing Patients with Ovarian Cancer.
@nl
type
label
Cost Analysis of FDG PET for Managing Patients with Ovarian Cancer.
@en
Cost Analysis of FDG PET for Managing Patients with Ovarian Cancer.
@nl
prefLabel
Cost Analysis of FDG PET for Managing Patients with Ovarian Cancer.
@en
Cost Analysis of FDG PET for Managing Patients with Ovarian Cancer.
@nl
P2093
P1476
Cost Analysis of FDG PET for Managing Patients with Ovarian Cancer.
@en
P2093
Gary T. Smith
Joseph A. Thie
Karl F. Hubner
Thomas McDonald
P356
10.1016/S1095-0397(99)00013-8
P577
1999-03-01T00:00:00Z